Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.
Enorama Pharma AB (ERMA) - Net Assets
Latest net assets as of September 2025: Skr-4.65 Million SEK
Based on the latest financial reports, Enorama Pharma AB (ERMA) has net assets worth Skr-4.65 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr12.57 Million) and total liabilities (Skr17.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-4.65 Million |
| % of Total Assets | -36.97% |
| Annual Growth Rate | 11.36% |
| 5-Year Change | 339.11% |
| 10-Year Change | 19.6% |
| Growth Volatility | 335.06 |
Enorama Pharma AB - Net Assets Trend (2014–2024)
This chart illustrates how Enorama Pharma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enorama Pharma AB (2014–2024)
The table below shows the annual net assets of Enorama Pharma AB from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr7.80 Million | -60.06% |
| 2023-12-31 | Skr19.54 Million | -38.02% |
| 2022-12-31 | Skr31.52 Million | +47.63% |
| 2021-12-31 | Skr21.35 Million | +1101.69% |
| 2020-12-31 | Skr1.78 Million | -75.25% |
| 2019-12-31 | Skr7.18 Million | -57.81% |
| 2018-12-31 | Skr17.02 Million | +131.20% |
| 2017-12-31 | Skr7.36 Million | -18.93% |
| 2016-12-31 | Skr9.08 Million | +39.17% |
| 2015-12-31 | Skr6.52 Million | +145.26% |
| 2014-12-31 | Skr2.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enorama Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23961500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr9.45 Million | 121.09% |
| Other Components | Skr237.99 Million | 3049.97% |
| Total Equity | Skr7.80 Million | 100.00% |
Enorama Pharma AB Competitors by Market Cap
The table below lists competitors of Enorama Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clubhouse Media Group Inc
PINK:CMGR
|
$549.68K |
|
Alkame Holdings Inc
PINK:ALKM
|
$549.92K |
|
Fuse Medical Inc
PINK:FZMD
|
$550.43K |
|
FINNING INTL (CIH.SG)
STU:CIH
|
$551.51K |
|
The Ether Fund
OTCGREY:QETHF
|
$549.37K |
|
Arrayan Acciones Chilenas FIP
SN:CFIARRAA-E
|
$549.28K |
|
Taurus Gold Corp.
PINK:TARGF
|
$548.99K |
|
MSCI WORLD CLIMATE CHAN NETR US
STU:PQIA
|
$548.70K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enorama Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,538,000 to 7,803,000, a change of -11,735,000 (-60.1%).
- Net loss of 43,806,000 reduced equity.
- Share repurchases of 40,402,000 reduced equity.
- New share issuances of 40,402,000 increased equity.
- Other comprehensive income increased equity by 192,177,000.
- Other factors decreased equity by 160,106,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-43.81 Million | -561.4% |
| Share Repurchases | Skr40.40 Million | -517.78% |
| Share Issuances | Skr40.40 Million | +517.78% |
| Other Comprehensive Income | Skr192.18 Million | +2462.86% |
| Other Changes | Skr-160.11 Million | -2051.85% |
| Total Change | Skr- | -60.06% |
Book Value vs Market Value Analysis
This analysis compares Enorama Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.68x to 2.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.57 | Skr0.39 | x |
| 2015-12-31 | Skr1.41 | Skr0.39 | x |
| 2016-12-31 | Skr2.16 | Skr0.39 | x |
| 2017-12-31 | Skr1.53 | Skr0.39 | x |
| 2018-12-31 | Skr3.21 | Skr0.39 | x |
| 2019-12-31 | Skr1.07 | Skr0.39 | x |
| 2020-12-31 | Skr0.26 | Skr0.39 | x |
| 2021-12-31 | Skr2.84 | Skr0.39 | x |
| 2022-12-31 | Skr3.32 | Skr0.39 | x |
| 2023-12-31 | Skr0.71 | Skr0.39 | x |
| 2024-12-31 | Skr0.15 | Skr0.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enorama Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -561.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -277.82%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 2.04x
- Recent ROE (-561.40%) is below the historical average (-277.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -0.75% | -1.45% | 0.37x | 1.39x | Skr-286.00K |
| 2015 | -10.06% | -32.90% | 0.22x | 1.41x | Skr-1.31 Million |
| 2016 | -86.31% | -196.33% | 0.29x | 1.50x | Skr-8.74 Million |
| 2017 | -118.94% | -556.67% | 0.10x | 2.10x | Skr-9.49 Million |
| 2018 | -96.01% | -310.87% | 0.14x | 2.28x | Skr-18.04 Million |
| 2019 | -344.33% | -324.83% | 0.18x | 5.93x | Skr-25.44 Million |
| 2020 | -1345.02% | -1113.75% | 0.05x | 23.02x | Skr-24.08 Million |
| 2021 | -133.67% | -258.64% | 0.22x | 2.39x | Skr-30.68 Million |
| 2022 | -132.53% | -610.19% | 0.14x | 1.55x | Skr-44.93 Million |
| 2023 | -228.34% | -3285.20% | 0.04x | 1.76x | Skr-46.57 Million |
| 2024 | -561.40% | -277.82% | 0.99x | 2.04x | Skr-44.59 Million |
Industry Comparison
This section compares Enorama Pharma AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $103,579,034
- Average return on equity (ROE) among peers: -52.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enorama Pharma AB (ERMA) | Skr-4.65 Million | -0.75% | N/A | $549.55K |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $21.33 Million |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $14.51 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.34 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $570.29K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.01 Million |